🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating worldwide, with figures suggesting more than 82 million instances per year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of rising global incidence, escalating drug resistance and the very limited available drugs at this time.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in December for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Results and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which involves a dual-drug approach. The study included over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of developing nations.

Medical professionals treating patients have expressed optimism. Access to a one-pill regimen such as this is hailed as a "critical tool" for managing the epidemic. This is deemed essential to lessen the impact of the disease for patients and to halt the transmission of untreatable gonorrhoea around the world.